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Abstract
AIM: To examine the calcium metabolism of colorectal cancer
(CRC) in patients with colorectal cancer and control patients.
METHODS: Seventy newly diagnosed CRC patients were
included. The healthy control group was age and gender
matched (n=32). Particular attention was devoted to the
relationship between serum calcium of patients, and levels
of AFP, CEA, carbohydrate antigen 19-9 (CA 19-9) (that could
be considered as prognostic factors). Furthermore, the
Ca-sensing receptor (CaSR) gene A986S polymorphism was
investigated in these patients, as well as the relationship
between different CaSR genotypes and the data stated above.
RESULTS: A lower level of ionized calcium (also corrected
for albumin) was found in the serum of CRC patients with
normal 25(OH) vitamin D levels. The ionized calcium
concentration was inversely correlated with the serum level
of CA 19-9. There was no difference in the distribution of
CaSR genotypes, between CRC patients and general
population. The genotypes did not correlate with other data
examined.
CONCLUSION: Based on these results, lower levels of
serum calcium might be a pathogenic and prognostic factor
in colorectal cancer.
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INTRODUCTION
Mortality statistics of the developed countries show that
colorectal cancer (CRC) is the second leading cause of death.
Even though tumorigenesis is a complex process, epidemiological
and experimental data indicate that beside the genetic factors,
eating habits (and thus the calcium intake) also play a key role
in the development of CRC[1]. In the past few years, we have
learned more and more about the process, but not every possible
factor has been uncovered yet.
     Several in vitro and in vivo studies have confirmed the
chemopreventive role of calcium in CRC[1-5]. The experimental
data showed that there was a definite connection between low
calcium and vitamin D intake and the prevalence of CRC[6,7].
Some researchers described a protective effect against the
development of CRC, when the calcium intake was 1 200 mg
daily[8]. Alimentary calcium (among others) together with bile
acids creating insoluble calcium-soaps inhibite the cytotoxic
effect of fatty acids in the bowel, thus protecting the mucus
membrane[9-12].
      According to twin studies, serum calcium level was mostly
determined by genetic factors[13]. One of the key factors of this
determination is the calcium-sensing receptor (CaSR), which
by sensing the concentration of calcium in target organs could
respond to the changes of calcium level, thus regulating calcium
homeostasis[13]. Also, a connection has been found between
the CaSR gene A986S genotypes (986 Ala/Ser) and serum
calcium concentrations within the normal range in healthy adult
population[14].
      In our work, we examined the calcium metabolism of 70
recently diagnosed CRC patients and analyzed its possible
role in the pathogenesis of CRC, and also the relationship
between serum levels of AFP, CEA, CA 19-9 (that could be
considered as prognostic factors) and parameters of calcium
metabolism. Furthermore, we examined the genotype frequencies
(CASR A986S) of our patients and the relationship between
genotypes and laboratory parameters of calcium homeostasis
and tumor markers.
MATERIALS AND METHODS
Patients
Seventy newly diagnosed CRC patients were examined. All
the subjects were in good general conditions. Colonoscopy
was performed partly for screening purposes (n=10), partly
due to symptoms (n=60), such as abdominal pain, discomfort
and flatulence, anemia, hematochezia, changes in bowel habits,
and partly to search for primary tumor (for example in cases
of hepatic metastasis). In each selected case, the histological
diagnosis was adenocarcinoma. Clinical stage was Dukes
A: 20, B: 32, C: 18. Five patients had liver metastasis at
presentation. The clinical data of the patients are presented in
Table 1. An age and gender adjusted healthy control group
(n=32) was selected for comparison of the laboratory data.
The CASR genotype frequency was compared to the genotype
frequency of our previously determined control group,
consisting of 201 healthy adults. Written informed consent was
obtained from all subjects. The study was approved by the
Semmelweis University Regional and Institutional Committee
of Science and Research Ethics (141/2003).
Laboratory parameters
To analyze the calcium metabolism of the subjects, serum
calcium, phosphate and albumin levels were determined by
photometric analysis (Roche, Mannheim, Germany). Ionized
calcium levels were also measured in a similar way (Easy-
Lite, Bedford, USA). The calcium levels were also corrected
to the serum albumin levels (corrected calcium). HPLC (Biorad,
Hercules, USA) was used to measure the serum 25(OH) vitamin
D levels, while serum levels of parathyroid hormone (PTH)
were determined by chemiluminescence assay (Elecsys/Roche,
Basel, Switzerland). To measure AFP, CEA and CA 19-9,
immunoassays (Axxym/Abbott, North Chicago, USA) were
utilized.
Sampling and histology
In each case, the diagnosis was established by colonoscopy
(Fujinon, Japan), and tissue samples were taken for histological
analysis.
Genotyping
The polymorphic region of CaSR gene was amplified by allele
specific PCR technique. The following primers were used:
primer M: 5’ ACG GTC ACC TTC TCA CTG ACG TTT GAT
GAG CCT CAG AAG TAC T 3’ 43-mer; primer W: 5’ GCT
TTG ATG AGC CTC AGA AGA TCG ’ 24-mer; and primer
R: 5’ CTC TTC AGG GTC CTC CAC CTC T 3’ 22-mer
(10 mmol/L final concentration). PCR reaction was carried out
in 20 mL final volume containing: 2 mL 10× Mg free reaction
buffer, 4 mL dNTP (1 mmol/L), 1.2 mL 25 mmol/L MgCl2,
1 mL DNA (25 ng/mL), 3-2-1 mL (primer R, -W, -M), 0.1 mL
(0.5 U/mL) Taq (Promega, Madison, USA) and 5.7 mL 2D
PCR water. The PCR conditions were at 94  for 12 min,
35 cycles at 94  for 20 min, at 55  for 20 min, at 72  for
30 min and  at 72  for 5 min. There were two types of CaSR
allels, the allele A and allele S, so the genotypes were AA, AS,
SS. Electrophoretic separation was carried out in a 70 g/L
Spreadex/acrilamide-bis (29:1) gel (Elchrom, Cham,
Switzerland). For the PCR reaction; Hybaid express
thermocycler (Teddington, Middlesex, UK) was used.
Statistics
As the first step, the distribution of continuous parameters
was analyzed (Kolmogorov-Smirnov test). Logarithmic
transformation was performed as needed. However, results
were presented using the original units for easier understanding.
The average values for CRC and the control population as well
as difference between patients with different genotypes were
compared using Student t test with separate variance estimates.
c2 test was used to describe the relation between the allele
frequency and tumor localization. Finally, we used parametric
correlation (Pearson) to describe the relationship between
tumor markers and the calcium homeostasis. A P value <0.05
was considered statistically significant. All the statistical
analyses were performed using SPSS 9.0 for Windows.
RESULTS
By examining the calcium metabolism of CRC patients, we
found that the serum calcium, ionized and corrected calcium
levels of our patients were significantly lower, than those of
controls. These calcium levels were at the lower limits of the
normal range. Serum phosphate and albumin levels were also
determined, which were in the lower end of the normal range
(Table 1).
     There was no difference in serum 25(OH)-vitamin D and
PTH values between patients and controls (Table 1). When
examining the correlation between calcium metabolism and
CEA, AFP, CA 19-9 tumor markers, we found that the ionized
calcium levels of our patients were inversely correlated with
the serum level of CA 19-9 tumor marker (Table 2).
     There was no significant difference in the CaSR A986S
genotype frequency between healthy population and CRC
patients [(CRC: AA=51/70(73%), AS=19/70(27%), SS=0/70
(0%); control group: AA=145/201(72%), AS=54/201(27%),
SS=2/201(1%)].
     In case of the different CaSR A986S genotypes of CRC
patients, no difference was observed in the examined
biochemical parameters and tumor markers (Table 3). Different
alleles or genotypes did not show any correlation with the
localization of tumor.
Table 1  Laboratory data of CRC patients (mean±SE)
                                 CRC           Control            P           Normal value
Calcium (Ca)   2.26±0.17      2.45±0.09     0.0001    2.25-2.61 mmol/L
Corrected Ca   2.26±0.14      2.37±0.11     0.0001    2.25-2.61 mmol/L
Ionized calcium  1.07±0.07        1.2±0.05     0.0001    1.05-1.25 mmol/L
Phosphate   1.07±0.13        1.2±0.22     0.006      0.85-1.45 mmol/L
Albumin   39.5±4.61    43.87±4.37     0.0001       35-50 g/L
AFP   4.19±2.85      3.34±1.58        NS           0-15 ng/L
CEA 18.84±69         1.79±1.86     0.043          0-10 ng/L
CA 19-9 86.49±406     10.20±9.95        NS           0-37 ng/L
PTH   38.2±16.8      41.5±14.6        NS         10-65 pg/mL
25(OH) vit. D   44.7±73.8    46.84±13.7        NS         20-60 ng/L
Age (yr)   65.6±10.9      63.6±8.2          NS                  -
NS=no significant difference.
Table 2  Correlation between tumor marker levels and param-
eters of calcium metabolism of CRC patients
                  Ca      Corrected    P        Ca2+    Albumin   PTH    25 (OH)
                                   Ca                                                                 vit. D
AFP     0.67       0.33       0.53       0.40         0.80       0.87         0.30
CEA     0.21       0.79       0.80       0.23         0.15       0.94         0.95
Ca19-9     0.57       0.57       0.63       0.007       0.10       0.74         0.94
Table 3  Laboratory parameters associated with different CaSR
A986S genotypes (mean±SE)
                                              AA                          AS                       P
Calcium 2.23±0.16    2.31±0.18         NS
Corrected Ca 2.24±0.12    2.30±0.14         NS
Phosphate 1.07±0.13    1.08±0.11         NS
Ionized calcium 1.07±0.08    1.09±0.07         NS
Albumin             39.61±4.40  39.20±5.30         NS
AFP 4.18±2.96    4.29±2.68         NS
CEA   9.2±23.8       45±125         NS
CA 19-9    68±379     143±492         NS
PTH 37.3±14.2    41.2±23.0         NS
25(OH) vit. D    51±85    27.3±11.4         NS
Age (yr)             66.18±10.96    64.8±11.2         NS
NS=no significant difference.
DISCUSSION
The results of our study support the role of low serum calcium
in the pathogenesis of CRC. Contrasting to previous data of
others, we found that beside normal vitamin D values the level
of calcium and the concentration of serum phosphate were
both lower than that of controls[7], suggesting that in CRC the
function of vitamin D receptor (VDR) might be damaged. Our
previous study corroborates this hypothesis since we showed
that oncogene (HER-2) expression correlated with VDR
genotypes in CRC patients[15].
      Western style diet (low in calcium and vitamin D and high
in fat) has been shown to induce hyperproliferation in colonic
epithelial cells. This cell proliferation could be inhibited by calcium
and vitamin D supplementation[10,16,17]. By increasing calcium
intake, the number of apoptotic cells in colon epithelium increased,
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as well[18]. Based on several human studies, high calcium and
vitamin D intake might prevent CRC development[1,3,5,6]. A
prospective study claimed that the frequency of CRC was three
times less in those patients whose serum vitamin D level was
above 20 ng/mL[7]. More than 3.75 mg daily vitamin D intake
appeared to reduce 50% incidence of CRC, while 1 200 mg daily
calcium intake decreased 75% of its incidence[7,8].
     Low calcium level may influence CRC pathogenesis in
several ways. Calcium ion (Ca2+) is needed for cell proliferation
and differentiation. On the other hand, Ca2+ could play an
important role in intercellular connections and signal-
transduction cascades[19-24]. Furthermore, it has an influence
on the cell-cycle regulatory genes (p53, K-ras, epidermal
growth factor) that had a well-documented role in CRC
pathogenesis[25,26]. The functions mentioned above are mediated
partly through CaSR. Similarly to other tissues, CaSR could
be detected in normal colon epithelial cells as well. Besides,
stimulation of the CaSR could increase the expression of E-
cadherin and decrease that of beta-catenin. E-cadherin is the
inductor of cell differentiation while beta-catenin is responsible
for the genesis of malignant phenotype. The fundamental
question is whether the low serum calcium level influencing
CRC development is present during a life-long period or
emerges only in a phase of the patient’s life right before the
appearance of cancer. Answering this question is crucial in
deciding when to start chemoprevention.
       A986S polymorphism of the CaSR gene has been suggested
to have a role in the development of parathyroid adenoma. Others
have demonstrated that healthy women with CaSR 986 AA
homozygote had lower levels of serum calcium compared to
women having AS heterozygote and SS homozygote CaSR
986 alleles[14]. Earlier, we demonstrated that CaSR A986S allele
frequencies in CRC patients were not different from those in
healthy subjects. However, patients with homozygote AA
genotype had a significantly higher UICC stage at the time of
discovery compared to the heterozygote AS patients. We could
not find an association between serum calcium concentrations
and CaSR A986S genotypes in our CRC subjects. We also
could not detect a correlation between CaSR polymorphism
and CRC. The role of CaSR A986S polymorphism in CRC
development requires further investigation.
     A large array of evidence indicates that CA 19-9 tumor
marker had a prognostic role in CRC. Elevated serum levels
were associated with the recurrence of CRC or the presence of
metastasis. In our patients, serum calcium levels inversely
correlated with CA 19-9 concentration, which could support
the significance of serum calcium not only as a pathogenic
factor but also as a prognostic factor.
       In conclusion, our results further strengthen the possibility
that serum calcium might be a pathogenic and prognostic factor
in the development of colorectal cancer. Our data draw attention
to the possibility that by increasing calcium intake, the multi-
leveled pathogenic process leading to tumorigenesis might be
influenced. In order to prove this, further studies are necessary.
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